Alain Mina, MD
Assistant Professor of Medicine (Medical Oncology & Hematology)Cards
About
Research
Publications
2026
Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy
Mina A, Xu Y, Kapustyan T, Dhalla M, Chen C, Kamalakar R, Lin C, Ma E, Montez M, Wu Z, Yee T, Sun H, Rava A, Kim S, Huntington S, Zeidan A. Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy. Leukemia & Lymphoma 2026, ahead-of-print: 1-9. PMID: 42437458, DOI: 10.1080/10428194.2026.2691911.Peer-Reviewed Original ResearchMenin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis
Alhajahjeh A, Beke K, Grimshaw A, Aguirre L, Mina A, Podoltsev N, Mendez L, Stahl M, Zeidan A, Bewersdorf J. Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis. Leukemia & Lymphoma 2026, 67: 1662-1674. PMID: 42251692, DOI: 10.1080/10428194.2026.2682397.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDesmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease
Zhao A, Pirsl F, Parkin J, Mina A, Hishmeh R, Holtzman N, Schulz E, Pavletic S, Jurdi N. Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-versus-Host Disease. Transplantation And Cellular Therapy 2026, s2666-6367(26)00427-6. PMID: 42208939, PMCID: PMC13403212, DOI: 10.1016/j.jtct.2026.05.034.Peer-Reviewed Original ResearchTargeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine
Mina A, Calvo K, McKinnon K, Raman A, Wang W, Cunningham L, Liu Y, Alexander R, Larson D, Pavletic S, McGraw K. Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine. Leukemia & Lymphoma 2026, 67: 1740-1748. PMID: 42047494, DOI: 10.1080/10428194.2026.2661078.Peer-Reviewed Original ResearchAcute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States
Bewersdorf J, Wang R, Mendez L, Mina A, Aguirre L, Stahl M, Zeidan A, Ma X, Podoltsev N. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer 2026, 132: e70415. PMID: 42033416, DOI: 10.1002/cncr.70415.Peer-Reviewed Original ResearchA 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Bewersdorf J, Mina A, Stahl M, Zeidan A. A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions. Nature Reviews Clinical Oncology 2026, 23: 481-500. PMID: 41981151, DOI: 10.1038/s41571-026-01141-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTargeting metabolism in acute myeloid leukemia: the next therapeutic frontier?
Mina A, Zeidan A. Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier? Chinese Clinical Oncology 2026, 15: 24-24. PMID: 42145008, DOI: 10.21037/cco-2025-1-191.Peer-Reviewed Original ResearchPharmacologic progress in higher-risk MDS: an uphill battle
Mina A, Zeidan A. Pharmacologic progress in higher-risk MDS: an uphill battle. Expert Opinion On Pharmacotherapy 2026, 27: 193-210. PMID: 41804943, DOI: 10.1080/14656566.2026.2644384.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies
Beauchamp E, Jain A, Clutter M, Nahotko D, Fajardo E, Vagadia P, Dunne S, Mina A, Fischietti M, Oku C, Blyth G, Mishra R, Karras E, Radecki S, Lantz C, Addepalli S, Modi M, Zou L, Cho B, Goo Y, Rossoff J, Fish E, Saleiro D, Schiltz G, Platanias L. Development of a SIN1 targeting inhibitor as a novel therapeutic approach for the treatment of malignancies. Molecular Cancer Therapeutics 2025, 25: 1111-1129. PMID: 41423418, PMCID: PMC12904549, DOI: 10.1158/1535-7163.mct-25-0298.Peer-Reviewed Original ResearchLuspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis
Alhajahjeh A, Woite N, Rolles B, Stempel J, Mina A, Mendez L, Kewan T, Podoltsev N, Stahl M, Grimshaw A, Zeidan A, Bewersdorf J. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Advances 2025, 9: 6511-6523. PMID: 40966428, PMCID: PMC12767819, DOI: 10.1182/bloodadvances.2025017611.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Clinical Care
Overview
Alain Mina, MD, specializes in medical oncology and hematology, with a focus on leukemia as well as stem cell transplants and cell therapy. Dr. Mina is dedicated to diagnosing and treating blood-related cancers, offering patients a combination of chemotherapy and advanced cellular therapies to manage their conditions effectively.
As an assistant professor of medicine at Yale School of Medicine, Dr. Mina conducts research of myeloid malignancies, such as myelodysplastic syndromes and acute myeloid leukemia. He focuses on discovering new therapies that can be tested in clinical trials.
Dr. Mina received his medical degree from the American University of Beirut in Lebanon, followed by a residency at University of Kansas Medical Center. He completed fellowships in hematology and oncology at McGaw Medical Center of Northwestern University, and in blood and marrow transplantation and cellular therapy at Stanford University Medical Center.
Clinical Specialties
News
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.